The cost of clinical trial complexity: how tailoring outsourcing solutions enable sponsors to keep pace

In clinical trials, priorities shift, portfolios evolve, timelines tighten and new challenges often emerge. At the same time, clinical trials are becoming larger and increasingly difficult to execute efficiently. Compared with a decade ago, the average Phase III clinical trial now involves longer timelines, more endpoints, more procedures, more countries and more investigative sites.¹ Against this backdrop, sponsors must compete for sites and specialized talent while facing continued pressure to accelerate development and control costs.

Beyond operational challenges, these additional layers of complexity translate into significant financial implications. A single day of delay represents hundreds of thousands of dollars in lost opportunity and direct study costs.² When trial complexity creates bottlenecks, resource constraints or execution delays, it has a tangible impact on the economics and success of a development program.

Sponsors may not be able to eliminate clinical trial complexity completely, but they may determine how effectively their operating model responds to it. As development needs become less predictable, sponsors must have outsourcing strategies that adapt without adding unnecessary friction.

Where complexity creates friction

Complexity rarely stems from one isolated challenge, but rather from overlapping difficulties and demands across different trial functions. A sponsor may be expanding into new regions while simultaneously managing a growing portfolio, navigating resource constraints and competing for specialized expertise. Protocol complexity, patient recruitment challenges and changing development priorities add further pressure.

An operating model that cannot adapt compounds these challenges. Internal teams may become overextended, capacity may no longer match demand, specialized expertise may be needed only at specific milestones and fragmented delivery across teams or providers may increase coordination requirements. That makes the outsourcing question broader than simply, “What should we outsource?” Sponsors should also consider asking, “What combination of support, expertise and operational ownership will help us manage complexity today while giving us the flexibility to respond to what comes next?”

Managing complexity starts with the right level of flexibility

There is no universal “right” outsourcing model because no two development programs are alike. Sponsors have different internal capabilities, infrastructure, therapeutic areas of expertise and strategic priorities. Rather than forcing an organization into a one-size-fits-all approach, tailoring outsourcing solutions provides a framework for designing an engagement around a sponsor’s specific needs.

Depending on the challenge, that may take several forms:

• Full-service outsourcing (FSO) arrangements provide complete end-to-end outsourcing of clinical trial activities. They are particularly valuable for sponsors seeking end-to-end program execution, those with limited internal resources and capabilities or those looking for reduced management burden.
• Functional service provider (FSP) partnerships offer support for specific functions across protocols, products or portfolios. They are attractive to sponsors seeking specialized expertise, long-term portfolio support or scalable resources while retaining greater control and visibility of clinical development operations.
• Mixed FSP/FSO models use a customized combination of FSP and FSO frameworks to create bespoke solutions tailored to meet specific customer needs. These arrangements are valuable for sponsors looking to balance control and flexibility, support complex portfolios, access specialized expertise or scale efficiently as resource requirements and strategic priorities evolve.

The strategic value of tailoring outsourcing solutions lies in adaptability. The ideal outsourcing partner adjusts the balance of control, accountability, expertise, resources, systems and contracting structures to create operating models aligned with sponsor needs and evolves as those needs change.

Tailoring the model to the complexity

Different sources of complexity might call for different approaches. A sponsor with limited internal bandwidth, for example, may benefit from an FSO arrangement that provides end-to-end execution and a single accountable partner. An organization with established infrastructure but gaps in capacity or specialized expertise may want to use an FSP solution to expand its capabilities while maintaining greater operational control. When a sponsor is managing a complex portfolio or undergoing changes, a mixed FSP/FSO model approach could provide a precise balance of end-to-end support and specialized functional expertise.

The right outsourcing solution is therefore not necessarily one model. It is the combination of resources, responsibilities and expertise that complements the sponsor’s capabilities, leverages its strengths and adapts as its needs evolve.

What adaptability looks like in practice

Having multiple delivery models available is only part of the equation. Sponsors should also consider whether an outsourcing partner can design, integrate and evolve those models around their changing needs. That requires an outsourcing partner with a consultative approach, deep clinical and operational experience, comprehensive therapeutic and functional expertise, access to specialized and scalable talent, and the ability to establish clear governance and shared accountability. The goal should be to complement the sponsor’s existing capabilities and create an engagement that adapts alongside the organization, resulting in less friction, more predictable execution and faster progress.

At the PPD™ clinical research business of Thermo Fisher Scientific, we work collaboratively with sponsors to build bespoke solutions around their capabilities, challenges and objectives, rather than simply offering multiple outsourcing models.  Our clinical and operational experience, therapeutic and functional expertise and access to scalable global talent, combined with the broader capabilities of Thermo Fisher Scientific, help sponsors cut through complexity and keep pace with change.

Those partnerships extend beyond staffing arrangements and cost structures. By operating as an extension of sponsor organizations, our staff become an integral part of your team, contributing their knowledge and insights, bringing fresh perspectives and implementing innovative strategies that support your goals and timelines.

Complexity calls for adaptability

Clinical development complexity is unlikely to disappear. In fact, it is likely to continue to grow, and that complexity often translates into greater costs, longer timelines and additional operational burden. However, sponsors control how they respond to this challenge.

The right outsourcing strategy allows sponsors to access expertise as needs change, scale resources more effectively, maintain the desired level of operational control and preserve continuity through periods of growth or transition. The right solution is the one designed around an organization’s capabilities, needs and challenges today while being flexible enough to evolve for what comes next. For sponsors, that means looking for a partner that collaboratively designs, integrates and evolves the operating model over time to address today’s challenges while building a stronger, more resilient clinical development ecosystem for the future.

Cut through clinical trial complexity

Discover how the PPD clinical research business tailors outsourcing solutions to complement your capabilities, leverage your strengths and address evolving trial challenges to support today’s priorities while preparing your clinical development programs for what comes next.

Download our eBook